This item still needs to be validated !
Title: Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group
Authors: Bruntsch, U ×
Heinrich, B
Kaye, S B
de Mulder, P H
Van Oosterom, Allan
Paridaens, Robert
Vermorken, J B
Wanders, J
Franklin, H
Bayssas, M #
Issue Date: Jan-1994
Series Title: European journal of cancer (Oxford, England : 1990) vol:30A issue:8 pages:1064-7
Abstract: Docetaxel (Taxotere), an analogue of paclitaxel, was tested in a phase II study in advanced renal cell carcinoma. Consenting patients with measurable lesions, adequate organ functions and no prior chemotherapy received 100 mg/m2 of docetaxel as a 1-h infusion every 3 weeks. No premedication to avoid hypersensitivity reactions or nausea and emesis was given. 32 eligible patients received 100 treatment cycles. Short-lasting neutropenia was the dose-limiting toxicity. Acute hypersensitivity reactions (HSR), oedema and skin changes were other important side-effects. HSRs regressed spontaneously or were treated with antihistamines with or without corticosteroids. One partial remission was documented. At the dose and schedule used, docetaxel has only low activity against renal cell carcinoma.
ISSN: 0959-8049
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Oncology - miscellaneous
Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science